Neutra Corp. is an early-stage company that sells hemp-derived nutraceutical products, primarily delta-8-THC and other cannabinoid products, under its own brand. Neutra uses a private-label model, outsourcing manufacturing to third-party contract manufacturers and selling products online. Neutra has also partnered with Artillery Labs to sell CBD products online. The company has generated only limited revenue since founding and has not yet fully commercialized its business. Neutra's acquisition of Vivis Corporation added a significant royalty burden — its CEO receives 40% of gross revenue until $100K is paid, then 25% until another $100K is paid, then 10% of gross revenue in perpetuity. The company acknowledges it lacks sufficient capital to execute its business plan and depends on raising additional financing to survive. Regulatory risk is the central issue facing the business: the DEA has signaled that hemp-derived delta-8-THC may be illegal under federal law, several states have already banned it, and the FDA continues to scrutinize cannabinoid products over health concerns including liver toxicity. Amendments to the federal PACT Act also complicate online sales of certain products, directly affecting Neutra's primary distribution channel. The legal landscape for hemp-derived cannabinoids remains unsettled, and future federal or state legislation could materially impair or shut down operations.